Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Prevention of Stroke or Systemic Embolism Clear all

Terminated Phase 3 Interventional Results available

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

NCT05643573

View directory record Official record

Conditions: Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
Interventions: Asundexian (BAY2433334), Apixaban, Asundexian matching placebo, Apixaban matching placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 14,830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 163
States / cities: Dothan, Alabama • Fairhope, Alabama • Mobile, Alabama + 144 more

Source: ClinicalTrials.gov public record

Updated Dec 8, 2024 · Synced May 22, 2026, 12:54 AM EDT

Completed Phase 4 Interventional Results available

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557

View directory record Official record

Conditions: Atrial Fibrillation
Interventions: pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 1,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 81
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more

Source: ClinicalTrials.gov public record

Updated Oct 4, 2015 · Synced May 22, 2026, 12:54 AM EDT